key: cord-0907115-x5t3hl40 authors: Herman, Lore; De Smedt, Stefaan C.; Raemdonck, Koen title: Pulmonary surfactant as a versatile biomaterial to fight COVID-19 date: 2021-11-20 journal: J Control Release DOI: 10.1016/j.jconrel.2021.11.023 sha: a9c0bc1b3e7ef0d8cac1db69236d628f514287b6 doc_id: 907115 cord_uid: x5t3hl40 The COVID-19 pandemic has wielded an enormous pressure on global health care systems, economics and politics. Ongoing vaccination campaigns effectively attenuate viral spreading, leading to a reduction of infected individuals, hospitalizations and mortality. Nevertheless, the development of safe and effective vaccines as well as their global deployment is time-consuming and challenging. In addition, such preventive measures have no effect on already infected individuals and can show reduced efficacy against SARS-CoV-2 variants that escape vaccine-induced host immune responses. Therefore, it is crucial to continue the development of specific COVID-19 targeting therapeutics, including small molecular drugs, antibodies and nucleic acids. However, despite clear advantages of local drug delivery to the lung, inhalation therapy of such antivirals remains difficult. This review aims to highlight the potential of pulmonary surfactant (PS) in the treatment of COVID-19. Since SARS-CoV-2 infection can progress to COVID-19-related acute respiratory distress syndrome (CARDS), which is associated with PS deficiency and inflammation, replacement therapy with exogenous surfactant can be considered to counter lung dysfunction. In addition, due to its surface-active properties and membrane-interaction potential, PS can be repurposed to enhance drug spreading along the respiratory epithelium and to promote intracellular drug delivery. By merging these beneficial features, PS can be regarded as a versatile biomaterial to combat respiratory infections, in particular COVID-19. In December 2019, the Chinese authorities identified severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as a new emerging β-coronavirus, capable of infecting humans and causing respiratory pathology. Infection with SARS-CoV-2 can result in the development of coronavirus disease-19 , which poses a serious threat to global public health, echoed by an estimated global mortality rate of more than four million people, as reported by the World Health Organization (WHO) [1] . Since its emergence, SARS-CoV-2 has rapidly spread across countries by which, as of March 2020, the WHO officially declared the outbreak as a pandemic. This health crisis led to worldwide efforts to combat COVID-19 by directly targeting SARS-CoV-2 infection (e.g. with antivirals), symptomatic treatment (e.g. via steroids), as well as through the optimization and standardization of supportive care management such as prone positioning and oxygenation [2] [3] [4] . All these efforts have the goal to prevent the development of respiratory failure, the most common cause of COVID-19 mortality [5] . Importantly, global vaccination campaigns are currently ongoing and will further progress in the coming months, leading to a reduction of infections, hospitalizations and mortality [6] . However, the availability of both preventive measures as well as (combination) therapies for already infected patients might be most effective. Therefore, in response to the urgency to fight the escalating COVID-19 pandemic, many existing drugs have been screened surfactant recycling pathway to target specific cell types such as type II pneumocytes or alveolar macrophages (AMs) [38] [39] [40] . Secondly, besides improving the extracellular availability of various therapeutics in the lung, PS has the newfound potential to promote the intracellular delivery of membrane-impermeable drugs. In particular, inhalation therapy with small interfering RNA (siRNA) is a promising approach to address acute respiratory viral infections, both by targeting viral proteins responsible for infectivity or replication, as well as host-related proteins that play a crucial role in viral infection or disease severity [41, 42] . To be functional, siRNA molecules require cytosolic delivery in the target cell of interest, for which they are typically encapsulated into nanoparticles (i.e. nanomedicines). Unfortunately, current state-of-the-art siRNA nanomedicines have difficulties in overcoming the many extraand intracellular barriers upon topical administration to the lung, leading to inefficient cytosolic delivery [43, 44] . In this regard, it was recently disclosed by Raemdonck and coworkers that exogenous PS has the unexpected property of promoting cytosolic siRNA delivery by polymeric nanomedicines [45] [46] [47] [48] [49] [50] . As such, exogenous PS can be regarded as a multifaceted biomaterial, enabling both direct treatment of COVID-19-related lung dysfunction as well as improved pulmonary delivery of small molecular-and macromolecular drugs. Coronaviruses belong to the family of Coronaviridae, which is further subdivided in four fatigue, myalgia and shortness of breath [53] . Especially older patients and patients with comorbidities such as obesity, diabetes and cardiovascular disease are at risk to develop respiratory failure with differing levels of hypoxia and diffuse lung infiltrates, associated with multi-organ failure and a high mortality rate, which necessitates hospitalization in the intensive care unit (ICU) and mechanical ventilation [2, 51, 54, 58, 61] . Of note, an increasing number of reports describe persistent complications post-infection that can last more than 4 weeks since the onset of symptoms [62] [63] [64] . PS is a surface-active biomaterial present at the thin layer of fluid that lines the alveolar epithelial surface, where it lowers the surface tension upon the formation of surfactant films at the air-liquid interface ( Figure 2A ) [65] . These interfacial films prevent alveolar collapse during expiration and thereby secures proper gas exchange [2, [66] [67] [68] . The presence of PS is crucial for pulmonary homeostasis, as its absence, deficiency or inactivation is correlated with severe pulmonary diseases [67, 69] . As shown in Figure 2B , PS is mainly composed of lipids shown in Figure 3 , these proteins can bind to a variety of receptors on innate immune cells (e.g. AMs and monocytes) via their carbohydrate recognition domain (CRD) or N-terminal region, thereby modulating cytokine production [75] [76] [77] . In addition, SP-A and SP-D can directly bind to soluble pro-inflammatory mediators such as tumor necrosis factor (TNF)α and lipopolysaccharide (LPS), which results in the inhibition of their downstream inflammatory actions ( Figure 3 ) [66, 78, 79] . Secondly, SP-A and SP-D bind to carbohydrates, phospholipids and glycolipids present on bacteria, viruses, yeasts and fungi, as well as to neutrophils and DNA via their CRD. This so-called 'opsonization' of pathogens and particles results in phagocytosis by immune cells such as AMs (Figure 3 ) [80] [81] [82] . Next to its crucial role in the protection of alveoli against potentially harmful matter, it is reported that SP-D contributes to surfactant homeostasis, as its absence results in the accumulation of PS in the airways due to an aberrant recycling process, although the exact underlying mechanism is still unknown [83, 84] . SP-B and SP-C are cationic and amphiphilic proteins, found in and between PS-associated lipid bilayers, and are essential for surfactant adsorption and stabilization at the alveolar air-liquid interface. Both proteins modulate membranes through combined electrostatic and hydrophobic protein-lipid interactions via cationic and aromatic residues, respectively 113]. Indeed, studies that compared animal-derived surfactants and protein-free synthetic surfactants showed that the latter failed to reduce the surface tension, due to the lack of SP-B and SP-C. In addition, it is reported that the administration of animal-derived surfactants results in lower needs for ventilation, reduced risk of pneumothorax and a lower mortality rate. Consequently, protein-free synthetic preparations were withdrawn from the market [114, 115] . A variety of animal-derived surfactants, which differ in origin and proteolipid content, are widely used in NRDS management (Table 1 ). In 1983, Curstedt and Robertson were the first to investigate the porcine-derived Poractant Alfa (Curosurf®) [2, 116] . Following studies led to the development of other animal-derived surfactants such as Beractant (Survanta®), Calfactant (Infasurf®) and SF-RI I (Alveofact®), all from bovine origin [104, 109, 117] . Various studies have compared the efficacy among different animal-derived preparations, however with conflicting results. In general, there are no significant differences between preparations from bovine origin. On the contrary, different studies reported on the superiority of Curosurf®, compared to both Survanta® and Infasurf®, albeit the administered dose of Curosurf® was systematically higher. Therefore, in order to draw clear conclusions, randomized and controlled trials that compare the efficacy of animal-derived surfactants at In contrast to SP-B, the specific amino acid composition of SP-C seems to be less important for its biophysical function, since SP-C analogues that solely mimic the α-helical structure of the transmembrane part of native SP-C can fully replicate its surface-active properties [127, 128] . This observation led to the development of SP-C33Leu, which deviates from native SP-C with respect to the removal or substitution of specific amino acids [104, 127, 129] . Currently, CHF5633 is the most advanced synthetic surfactant preparation and is under clinical investigation in a phase II trial for NRDS after proof of equal efficacy compared to Curosurf® and Survanta® in in vitro and in vivo models [130] [131] [132] [133] . CHF5633 contains peptide analogues of both SP-B and SP-C (i.e. Mini-BLeu and recombinantly synthesized SP-C33Leu), together with DPPC and POPG [2, 104] . In addition, a surfactant preparation that contains a mixture of DPPC, palmitoyloleoylphosphatidylcholine (POPC), POPG and SMB (i.e. Minisurf), is currently under preclinical investigation [134] . [24, 29, 30] . The main reason for these suboptimal outcomes is that next to the underlying surfactant deficiency, also inactivation of endogenous and exogenous surfactant occurs due to the presence of surface-active serum proteins and inflammatory molecules in the alveolar lumen, as will be explained later [140] . The high expression level of the ACE-2 receptor on the cellular surface of type II pneumocytes makes this cell type particularly vulnerable to infection with SARS-CoV-2. As a result, SARS-CoV-2 infection is reported to result in decreased endogenous PS levels, as well as altered PS composition and mutations [146] . Of importance, COVID-19-related mortality is mostly caused by a continuous, uncontrolled and exaggerated immune response. This is explained by the recruitment of inflammatory cells such as monocytes and macrophages, which subsequently secrete cytokines and chemokines, resulting in a so-called 'cytokine storm'. Subsequent neutrophil influx and degranulation leads to the destruction of type II pneumocytes and endothelial cells, resulting in the impairment of surfactant production and secretion and a disrupted endothelial barrier, which leads to serum leakage into the alveolar spaces and the development of CARDS ( Figure 4 ) [24] [25] [26] [27] 147] . Moreover, the ACE-2 receptor is involved in anti-inflammatory and antifibrotic mechanisms, which protect the lung from injuries. Extensive binding of SARS-CoV-2 to this receptor thus reduces its lung-protective capacities [27] . Surprisingly, CARDS does not follow the common clinical pattern in terms of lung mechanics, alveolar damage and radiological presentations typically seen with ARDS [148] , but is rather classified as an atypical pneumonia that resembles the pathophysiology of NRDS [24] . Based on the distinctive clinical manifestations of CARDS and the correlation to surfactant deficiency and inactivation, it is clear that results from past ARDS trials cannot simply serve as a reference to its potential in treating patients with CARDS [148] . Therefore, surfactant treatment to anticipate on the progression of severe lung injury in COVID-19 patients has J o u r n a l P r e -p r o o f been proposed as a potential treatment for COVID-19 [2, 24, 30] . Indeed, a study by Gerosa et al. showed that infection with SARS-CoV-2 results in the overexpression of SP-A inside the alveolar spaces. Here, it is important to note that SP-A is present in rather condensed masses which implies its inactivation or dysregulation [149] . Another study by Islam et al. subsequently showed that, next to affected levels and structures of SP-A, there is a dysregulation of a variety of genes involved in pulmonary surfactant production and activation, as well as its turnover and metabolism [150] . induced by an affected alveolar integrity [151] . Likewise, a study by Tong et al. revealed that serum SP-D levels were significantly higher in patients with severe COVID-19 [152] . As shown in Figure creating a steric and electrostatic barrier that prevents effective surfactant adsorption [169] [170] [171] . Interestingly, recent studies have shown that the addition of non-adsorbing hydrophilic macromolecules such as polyethyleneglycol (PEG) and hyaluronic acid also prevents surfactant inactivation in a similar way [140] . Since animal-derived SP-A and SP-D could also induce immunogenic reactions in adults, addition of these proteins to the formulation would require synthesis of human homologues compared to remdesivir [172] . In addition, it has been shown that rfhSP-D binds to the S1 subunit of the viral spike protein, thereby preventing its interaction with the ACE-2 receptor [173] . Secondly, the focus on the development of synthetic surfactants might become even more important in the treatment of CARDS. Indeed, synthetic surfactants seem more resistant to inactivation [174] . In addition, it has been reported that CHF5633 reduces LPS-induced proinflammatory cytokine release from human monocytes, a valuable property given the marked inflammatory nature of COVID-19 [175] [176] [177] . In addition to higher doses and/or more frequent administrations [178] , also an alternative pulmonary delivery mode might be required. In neonates suffering from NRDS, surfactants are typically administered via an intratracheal bolus instillation, yet this delivery mode is J o u r n a l P r e -p r o o f invasive and associated with a non-homogenous distribution throughout the lung tissue. Taking into account the larger surface area of the conducting airways in adults, there is a risk for more significant loss of surfactant along its way to the alveoli. Therefore, non-invasive delivery modes such as surfactant aerosolization using ultrasonic or jet nebulizers are currently under development [179] [180] [181] [182] , and have already proven to be safe in animal models without functional alterations of the surfactant preparation [183] [184] [185] . Based on the above-mentioned beneficial features of surfactant administration to COVID-19 patients, several clinical trials have been initiated to investigate the safety, efficacy and practical feasibility of this treatment option and are summarized in Table 2 [2,186]. [35] In addition, the off-label use of surfactants to treat CARDS has already been reported in the literature. Although validation on the efficacy, safety and feasibility by sufficiently powered clinical trials is required, the outcomes as mentioned above already give an optimistic indication on the potential of exogenous surfactant administration to COVID-19 patients. As the lungs are the major target tissue of SARS-CoV-2 infection, pulmonary delivery of COVID-19-targeting drugs is an attractive alternative for intravenous administration. Local application to the lung has a variety of advantages as it is non-invasive, grants direct access to target cells, allows a rapid onset of action and prevents systemic side effects [189, 190] . A variety of new and existing drug molecules and approaches are envisioned as a potential treatment for COVID-19, including antiviral therapies as well as therapeutics that target pathophysiological pathways associated to infection [2] . In this regard, this section will discuss the potential to exploit exogenous PS as a drug delivery vehicle to enhance drug spreading and adsorption after local pulmonary delivery, leading to improved therapeutic outcomes. Antiviral drugs might be most suitable for treating COVID-19, as they specifically target the viral life cycle-and viral spreading. As the pandemic unfolded, the number of clinical trials that evaluated the repurposing of existing drugs as antivirals concurrently increased, since this repurposing strategy has several advantages compared to the development of new drugs [191, 192] . However, the randomized evaluation of COVID-19 therapy (RECOVERY) trial showed no clinical benefit from the use of hydroxychloroquine or lopinavir/ritonavir [193, 194] . As a result, Gilead's remdesivir, a repurposed antiviral drug that acts as a nucleoside analogue to inhibit the RNA-dependent RNA polymerase of SARS-CoV-2 [195] , is the only antiviral drug Another approach to prevent viral entry is the development of monoclonal antibodies (mAbs) or antibody-based products that for example bind the viral spike protein, thereby blocking its HCAb (i.e. VHH VE) was able to neutralize SARS-CoV-2 by a rather unusual mode-of-action. Here, the binding of VHH VE to the RBD induced fusion, leading to irreversible changes in spike protein structure, thereby preventing its subsequent interaction with the ACE-2 receptor on host cell membranes. Importantly, VHH VE was also able to neutralize SARS-CoV-2 mutants [196] . Focusing on inhalation therapy, HCAbs have several advantages compared to conventional mAbs. First, they have a high robustness as they are able to refold after denaturation. In addition, they are small and have a high thermal-and chemical stability and solubility. Next to targeting the spike protein, also neutralization of inflammatory molecules such as interleukins can be of interest. In this regard, the RECOVERY trial probed the potential [197] . Since COVID-19 disease severity is correlated to inflammatory lung injury, the administration of corticosteroids is an arguable treatment option to temper inflammation pathways and prevent the development of respiratory failure. In this regard, the RECOVERY trial investigated the impact of oral and intravenous administered dexamethasone (once daily, 10 days) on the 28-day mortality. Dexamethasone treatment resulted in a lower mortality rate in patients that require invasive mechanical ventilation or oxygenation, compared to patients receiving usual care. As a result, next to remdesivir, also dexamethasone was approved for hospitalized COVID-19 patients requiring oxygenation with or without mechanical ventilation. Given the many advantages of local pulmonary delivery as described above and its wide application in other respiratory diseases including asthma and COPD, also inhalation corticosteroids ( [198] . A recent study by Yamaya et al. showed that pre-treatment of primary human nasal-and tracheal epithelial cells with a combination of budesonide, glycopyrronium and formoterol lowered viral titers of HCov-229E and modulated infection-induced inflammation by decreasing the release of IL-6, IL-8 and IFNβ [199] . In addition, budesonide and formoterol [200] . Notably, recent studies reported on the clinical potential of inhaled ciclesonide. Upon local administration, this corticosteroid has an antiinflammatory effect as well as antiviral activities, as it lowers SARS-CoV-2 replication and cytotoxic potential in Vero cells in vitro [201] . Following this data, Covis Pharma group recently announced favorable safety and efficacy results from a double-blind, randomized and controlled phase III trial investigating ciclesonide administration via a metered-dose inhaler (MDI) in non-hospitalized, symptomatic COVID-19 patients. Results showed faster relief of symptoms and a reduced risk for hospitalization by day 30, compared to placebo. Importantly, no adverse events were reported up to 60 days post-treatment [202] . To improve therapeutic results upon inhalation, Lammers et al. described the promise of dexamethasone nanomedicines. As the encapsulation of drugs into nanoparticles results in enhanced phagocytosis by AMs, dexamethasone will be more specifically delivered to the cells that play a key role in lung inflammation [203] . In general, despite the availability of many interesting drugs to treat COVID-19, deep penetration of drugs into the lungs and drug deposition in the alveolar spaces is challenging. Impaction of aerosolized drugs on bifurcations will lead to mucociliary clearance and hence subtherapeutic outcomes. Most important, as described above, critically ill COVID-19 patients additionally suffer from acute respiratory distress, which is correlated with the development of hypoxic, collapsed lung regions. These regions are even more difficult to reach following inhalation therapy due to a reduced surface area that is accessible for drug deposition and the inability of the patients to properly use inhalation devices [36] . In addition, liposomal surfactant carriers (i.e. drugs formulated inside surfactant liposomes, Figure 5 ) can mediate active targeting of drugs. As mentioned above, during consecutive breathing cycles, used PS components are released from surfactant films and recycled through uptake into type II pneumocytes and repackaging in LBs. Next to this, used PS components can also be processed and degraded by AMs. In case the PS-encapsulated drugs are carried along with this depleted pool of PS components, they can also benefit from this recycling mechanism to promote further spreading along the lung surface or enable internalization by these specific cell types [39, 40, 204] . Given the amphiphilic nature of PS, a variety of therapeutics with different physicochemical properties can be incorporated, even enabling combination therapy by loading several drugs into an exogenous lung surfactant formulation, as shown in Figure 5 [205] . Hidalgo et al. confirmed that hydrophobic drugs such as corticosteroids experience enhanced transport and spreading along the respiratory surface upon formulation in exogenous PS [206] . In addition, [205] . PS-assisted pulmonary drug delivery of other small molecules has also been investigated. Here, the immunomodulating agent tacrolimus retained its immunosuppressive efficacy after lung transplantation and in respiratory infections upon encapsulation in lung surfactant-like carriers. In addition, the combination of the aminoglycoside antibiotic tobramycin and clinical surfactant leads to improved survival rates in mice suffering from Klebsiella pneumonia infection [207, 208] . Next to small molecules, also the delivery of biological drugs including antimicrobial peptides, antibodies, antioxidant enzymes and viral particles have shown to benefit from this particular encapsulation approach [209] [210] [211] [212] . A recent publication reported on the potential of co-aerosolizing the cationic amphiphilic compound ambroxol and surfactant in the form of ambroxol-loaded-and coated DPPC nanoparticles as a treatment for CARDS. Ambroxol is a mucolytic drug that is widely used in a variety of pulmonary diseases [213] . Moreover, it is reported to have anti-inflammatory, antioxidant, antiviral and antibacterial properties, as well as to stimulate the production-and secretion of PS [214, 215] . Upon co-delivery, the surfactant fraction can supplement the After inhalation, siRNA molecules need to be safely guided to the target cell cytosol, for which they are generally formulated into nanoparticles. However, besides the many advantages of local pulmonary delivery of nanomedicines, the lung also poses many extra-and intracellular barriers that can hamper siRNA delivery [239, 240] . In general, predicting the fate of inhaled nanoparticles is complex since it is determined by a variety of parameters. Next to particlerelated properties (e.g. mean mass aerodynamic diameter (MMAD), hydrophobicity and charge), also patient-related properties (e.g. breathing patterns) as well as the anatomy, physiology and pathological state of the lung are involved. An important anatomical barrier towards pulmonary siRNA delivery is the highly branched structure of the lungs, where the fate of aerosolized particles following inhalation therapy will strongly depend on their MMAD. Nanomedicines formulated in aerosolized microparticles (e.g. dry powders or nebulized droplets) that sediment in the bronchial or alveolar region will subsequently need to cross the respiratory mucus or pulmonary surfactant layer to reach the underlying bronchial or alveolar epithelial cells, respectively [241] [242] [243] . In addition, nanoparticles are prone to clearance by respiratory immune cells such as macrophages, which can be present at both interfaces [244] . In this regard, investigating nanoparticle/PS interactions are crucial since such interactions can both alter the nanoparticles' distribution profile, targeting potential and drug delivery efficiency, as well as affect the endogenous PS layer [84] . However, the design of such studies is challenging since it requires the use of materials or models that closely resemble the composition of endogenous PS. Indeed, clinically used surfactants can be obtained easily but have several limitations; they are devoid of the hydrophilic proteins SP-A and SP-D and both the phospholipid-and SP-B/SP-C fractions are often lower compared to physiological conditions. Therefore, the use of patient-derived PS (e.g. via bronchoalveolar lavage) is more J o u r n a l P r e -p r o o f Journal Pre-proof desired, however requires more invasive procedures. Several studies report on the greater affinity of surfactant proteins to smaller particles, leading to enhanced toxicity of these particles towards endogenous PS [245] [246] [247] . In this regard, SP-A and SP-D will more easily adsorb to hydrophilic nanoparticles, leading to particle opsonization and enhanced uptake by AMs and lung dendritic cells [248, 249] . In addition, Wohlleben et al. showed that SP-A adsorption may induce interactions with PS lipids, thereby facilitating particle diffusion through the liquid phase and enhancing particle delivery to desired cell types [250] . On the other hand, SP-B and SP-C have a higher affinity for hydrophobic particles, which is more detrimental for the biophysical function of PS given the importance of SP-B and SP-C in surfactant adsorption and stability [204] . However, one of the most difficult barriers to overcome for siRNA therapeutics is situated at the intracellular level. When nanoparticles interact with the cellular plasma membrane, they are typically taken up via endocytosis, confining them inside early endosomes. These organelles further mature towards late endosomes and finally fuse with lysosomes, which are characterized by an acidic pH (~4. and the presence of degrading enzymes, including nucleases [254] . As the RNAi machinery resides in the cytosol, endosomal escape of nanoparticles and/or their siRNA cargo into the cell cytosol before lysosomal fusion occurs is required to induce target gene silencing. Despite the many efforts towards the design of J o u r n a l P r e -p r o o f effective nanoformulations in the last decades, even for state-of-the-art nanocarriers the endosomal escape efficiency remains very low (< 1-2%) [44] . Importantly, since the lungs of COVID-19 patients are already highly sensitized due to the activation of inflammatory pathways, not only an effective, but also a biocompatible nanoparticle for inhalation therapy of siRNA therapeutics is highly sought after. In this regard, exploiting bio-inspired materials is a research area gaining attention. As mentioned above, PS can be regarded as an extracellular barrier upon inhalation of nanomedicines. More specifically, surfactant components can adsorb to the surface of the nanoparticle, creating a biomolecular corona. In addition, due to the presence of negatively charged surfactant components (e.g. PG, PI and PS), there is a risk for nanocarrier aggregation or siRNA decomplexation prior to endocytic uptake [37, 84, 204, 255] . in vivo stability (e.g. mitigating the interaction with and decomplexation of siRNA by mucins and endogenous PS components), as well as nanocarrier biocompatibility [46] . Following in vivo studies that probed the administration of uncoated-and Curosurf®-coated siNGs via pharyngeal aspiration in mice showed that only the latter could induce gene suppression in resident AMs, reaching 70% knockdown of the pan-leukocyte marker CD45 at a dosage of 1 mg/kg [47] . Clinical translation of the above-mentioned core-shell nanocomposites requires testing the long-term stability as well as the delivery efficiency following aerosolization. In this regard, previous studies already showed the feasibility to lyophilize PS preparations of different origins without compromising its surface-activities [258] [259] [260] . Considering this, Merckx et al. assessed lyophilization of Curosurf®-coated siNGs, followed by reconstitution and nebulization using a state-of-the-art vibrating mesh nebulizer. Importantly, neither the lyophilization and reconstitution process, nor the subsequent nebulization negatively impacted the physicochemical properties and the biological performance of the particles. Of note, no stabilizing agents such as cryo-and lyoprotectants were required to achieve this feat [48] . Lastly, the deployment of siRNA-based antivirals can alleviate the challenges associated with small molecular antivirals as this therapy is highly specific, allows to target different genes of interest simultaneously and is able to inhibit otherwise undruggable targets. To guarantee target cell entry and protection of the siRNA payload from degradation, these molecules are generally formulated into nanosized carriers. Unfortunately, to date no nanoformulation is J o u r n a l P r e -p r o o f available that allows safe and efficient siRNA delivery following inhalation. In response to this unmet need, Raemdonck and co-workers disclosed the ability of the pulmonary surfactantassociated SP-B to enhance the cytosolic delivery of siRNA. Given its endogenous nature, pulmonary surfactant-based nanoparticles could pave the way to the development of biocompatible surfactant-inspired formulations that enable efficient delivery of antiviral siRNAs to the lungs of COVID-19 patients. Moreover, it is anticipated that such formulations could be more widely used for treatment of other respiratory pathologies as well. J o u r n a l P r e -p r o o f World Health Organization, WHO COVID-19 dashboard Optimizing supportive care in COVID-19 patients: A multidisciplinary approach Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia Analyzing the Global Impact of COVID-19 Vaccination Progress: A Result-oriented Storytelling Approach Drug repurposing: Progress, challenges and recommendations Pulmonary surfactant and drug delivery: Vehiculization, release and targeting of surfactant/tacrolimus formulations A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Master Regulator Analysis of the SARS-CoV-2/Human Interactome COVID-19 Treatment Guidelines : Do They Really Reflect Best Medical Practices to Manage the Pandemic ? WHO launches global megatrial of the four most promising coronavirus treatments Food and Drug Administration Approves Gilead's Antiviral Veklury® (remdesivir) for Treatment of COVID-19 Dexamethasone in Hospitalized Patients with Covid-19 Combination therapies for COVID-19: an overview of the clinical trials landscape COVID antiviral pills: what scientists still want to know Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results COVID -19: vaccination problems Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19 | BioSpace SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cell entry mechanisms of SARS-CoV-2 Coronavirus biology and replication: implications for SARS-CoV-2 Acute respiratory distress syndrome The acute respiratory distress syndrome Acute Respiratory Failure Animal-derived surfactants: Where are we? The evidence from randomized, controlled clinical trials Neonatal Outcomes by Mode of Delivery in Preterm Birth View project Animal-derived surfactants: where are we? The evidence from randomized, controlled clini Journal Pre-proof Surfactant for Treatment of ARDS in COVID-19 Patient Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury A clinical trial of nebulized surfactant for the treatment of moderate to severe COVID-19 (COVSurf) London's exogenous surfactant study for COVID19 (LESSCOVID) Curosurf® in adult acute respiratory distress syn-drome due to COVID-19 (Caards-1) The safety and preliminary efficacy of lucinac-in tant adults With COVID-19 Poractant Alfa -Curosurf and SARS-COV-19 ARDS (Covid-19) Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications Barrier or carrier? Pulmonary surfactant and drug delivery Pulmonary Surfactant and Drug Delivery: An Interface-Assisted Carrier to Deliver Surfactant Protein SP-D Into the Airways Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids Regulation of surfactant secretion in alveolar type II cells Prospects for RNAi Therapy of COVID-19 siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies? Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma Imagebased analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape The influence J o u r n a l P r e -p r o o f Journal Pre-proof of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels Bio-inspired pulmonary surfactant-modified nanogels: A promising siRNA delivery system Hybrid pulmonary surfactant-coated nanogels mediate efficient in vivo delivery of siRNA to murine alveolar macrophages Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy Surfactant Protein B Promotes Cytosolic SiRNA Delivery by Adopting a Virus-like Mechanism of Action Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat Neutrophils and COVID-19: The road so far Bats are natural reservoirs of SARS-like coronaviruses Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission SARS-CoV-2 pneumonia-receptor binding and lung immunopathology: a narrative review COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Implications of renal ACE2 expression in the age of COVID-19 Symptom Duration and Risk Factors for A Physiologically Informed Strategy to Effectively Open, Stabilize, and Protect the Acutely Injured Lung The Inhibitory Effect of Curosurf® and Alveofact® on the Formation of Neutrophil Extracellular Traps Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: Role of the different components in an efficient pulmonary surfactant Composition, structure and mechanical properties define performance of pulmonary surfactant membranes and films Diseases of Pulmonary Surfactant Homeostasis Structure of pulmonary surfactant membranes and films: The role of proteins and lipid-protein interactions Clearance and recycling of pulmonary surfactant P63 (CKAP4) as an SP-A receptor: Implications for surfactant turnover Diverse functions of pulmonary collectins in host defense of the lung Surfactant proteins A and D bind CD14 by different mechanisms OSCAR Is a Receptor for Surfactant Protein D That Activates TNF-α Release from Human CCR2 + Inflammatory Monocytes Leukocyte-associated Ig-like receptor-1 is a novel inhibitory receptor for surfactant protein D Surfactant Protein A Prevents IFNγ/IFN-γ Receptor Interaction and Attenuates Classical Activation of Human Alveolar Macrophages SP-D attenuates LPSinduced formation of human neutrophil extracellular traps (NETs), protecting pulmonary surfactant inactivation by NETs Surfactant protein A mediates pulmonary clearance of Staphylococcus aureus Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophages Surfactant protein A modulates cell surface expression of CR3 on alveolar macrophages and enhances CR3-mediated phagocytosis Surfactant Protein-D Regulates Surfactant Phospholipid Homeostasis in Vivo* Pulmonary surfactant and drug delivery: Focusing on the role of surfactant proteins Structure-function relationships in pulmonary surfactant membranes: From biophysics to therapy Pulmonary Surfactant Pathophysiology: Current Models and Open Questions Structure-function correlations of pulmonary surfactant protein SP-B and the saposin-like family of proteins The role of homodimers in surfactant protein B function in vivo Effects of oligomerization and J o u r n a l P r e -p r o o f Journal Pre-proof secondary structure on the surface behavior of pulmonary surfactant proteins SP-B and SP-C Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice Deficiency of Pulmonary Surfactant Protein B in Congenital Alveolar Proteinosis The NMR Structure of the Pulmonary Surf actant-Associated Polypeptide SP-C in an Apolar Solvent Contains a Valyl-Rich α-Helix Altered stability of pulmonary surfactant in SP-C-deficient mice Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred Surfactant protein C: Its unique properties and emerging immunomodulatory role in the lung Reversibility of lung inflammation caused by SP-B deficiency Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2 Surfactant Protein B Propeptide Contains a Saposin-Like Protein Domain with Antimicrobial Activity at Low pH Structural basis for interactions between lung surfactant protein C and bacterial lipopolysaccharide Synthetic peptides representing the N-terminal segment of surfactant protein C modulate LPS-stimulated TNF-α production by macrophages Synthetic surfactants with SP-B and SP-C analogues to enable Towards the Molecular Mechanism of Pulmonary Surfactant Protein SP-B: At the Crossroad of Membrane Permeability and Interfacial Lipid Transfer Dual Functioning Immune Molecules With Antiviral and Immunomodulatory Properties Surface Properties in Relation to Atelectasis and Hyaline Membrane Disease A Review of the Therapeutic Efficacy and Clinical Tolerability of a Synthetic Surfactant Preparation Neonatal Respiratory Distress Syndrome Animal-Derived Surfactants Versus Past and Current Synthetic Surfactants: Current Status History of Surfactant up to 1980 Controlled clinical trial of effects of alevaire mist on premature infants Proteolipid in bovine lung surfactant: Its role in surfactant function ARTIFICIAL SURFACTANT THERAPY IN HYALINE-MEMBRANE DISEASE Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome Animal derived surfactant extract versus protein free synthetic A unique story in neonatal research: The development of a porcine surfactant Surfactants: past, present and future Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials Peptide-based synthetic pulmonary surfactant for the treatment of respiratory distress disorders Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials Design of Surfactant Protein B Peptide Mimics Based on the Saposin Fold for Synthetic Lung Surfactants Role of the N-terminal seven residues of surfactant protein B (SP-B) Critical structural and functional roles for the N-terminal insertion sequence in surfactant protein B analogs Activity and biophysical inhibition resistance of a novel synthetic lung surfactant containing Super-Mini-B DATK peptide Phospholipid composition in synthetic surfactants is important for tidal volumes and alveolar stability in surfactant-treated preterm newborn rabbits Secondary structure and biophysical activity of synthetic analogues of the pulmonary surfactant polypeptide SP-C Synthetic peptide-containing surfactants. Evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution Structural and Functional Importance of the C-Terminal Part of the Pulmonary Surfactant Polypeptide SP-C A synthetic surfactant based on a poly-Leu SP-C analog and phospholipids: effects on tidal volumes and lung gas volumes in ventilated immature newborn rabbits Alterations of the C-terminal end do not affect in vitro or in vivo activity of surfactant protein C analogs New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs containing new synthetic surfactant for treatment of extremely immature lamb lung Advances in synthetic lung surfactant protein technology Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future Advances in synthetic lung surfactant protein technology Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: Experimental Acute respiratory distress syndrome Pathogenesis of indirect (secondary) acute lung injury Acute respiratory distress syndrome: The Berlin definition Anti-Inflammatory Effect of Anti-TNF-α SiRNA Cationic Phosphorus Dendrimer Nanocomplexes Administered Intranasally in a Murine Acute Lung Injury Model Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury The Role of Pulmonary Surfactants in the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Targeting potential drivers of COVID-19: Neutrophil J o u r n a l P r e -p r o o f Journal Pre-proof extracellular traps Vaccine against arteriosclerosis: an update Immunohistochemical findings in the lungs of COVID-19 subjects: evidence of surfactant dysregulation Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19? Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity Structural analogs of pulmonary surfactant phosphatidylglycerol inhibit toll-like receptor 2 and 4 signaling Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2 Nanodiscs as a therapeutic delivery agent: Inhibition of respiratory syncytial virus infection in the J o u r n a l P r e -p r o o f Journal Pre-proof lung Phosphatidylinositol inhibits respiratory syncytial virus infection Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection Phosphatidylglycerol suppresses influenza A virus infection Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein The trinity of COVID-19: immunity, inflammation and intervention Infection of human alveolar macrophages by human coronavirus strain 229E The SARS coronavirus spike Antiviral activity of recombinant porcine surfactant protein A against porcine reproductive and respiratory syndrome virus in vitro Nanoparticles modulate surfactant protein A and D mediated protection against influenza A infection in vitro Protective effect of surfactant protein D in pulmonary vaccinia virus infection: Implication of A27 viral protein Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo Insight into acute respiratory distress syndrome: From models to patients Overcoming inactivation of the lung surfactant by serum proteins: A potential role for fluorocarbons? Electrostatic Barrier to Recovery of Dipalmitoylphosphatidylglycerol Monolayers after Collapse Formation and structure of surface films: Captive bubble surfactometry A replication of SARS-CoV-2 in clinical samples Human surfactant protein D binds S1 and receptor binding domain of spike protein and acts as an entry inhibitor of SARS-CoV-2 pseudotyped viral particles in vitro Resistance of different surfactant preparations to inactivation by meconium Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes Effects of the new generation synthetic reconstituted surfactant CHF5633 on proand anti-inflammatory cytokine expression in native and LPS-stimulated adult CD14+ monocytes Anti-inflammatory effects of the new generation synthetic surfactant CHF5633 on Ureaplasma-induced cytokine responses in human monocytes Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: Impact on gas exchange and J o u r n a l P r e -p r o o f Journal Pre-proof haemodynamics Exogenous surfactant: Intubated present, nebulized future? Inhalation Techniques Used in Patients with Respiratory Failure Treated with Noninvasive Mechanical Ventilation How should aerosols be delivered during invasive mechanical ventilation? Aerosolized surfactants, anti-inflammatory drugs, and analgesics Ultrasonic and jet aerosolization of phospholipids and the effects on surface activity Aerosolized surfactant in lung-lavaged adult rats: Factors influencing the therapeutic response Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VȦ/Q̇) mismatch in a model of acute lung injury Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia London's exogenous surfactant study for COVID19 (LESSCOVID) Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study Pulmonary Drug Delivery, in: Handb. Non-Invasive Drug Deliv. Syst Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: Pulmonary compatible and site-specific drug delivery in lung metastases Drug repositioning: Identifying and developing new uses for existing drugs Drug repurposing: Progress, challenges and recommendations Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Mechanism of SARS-CoV-2 polymerase stalling by remdesivir Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells Budesonide and formoterol effects on rhinovirus J o u r n a l P r e -p r o o f Journal Pre-proof replication and epithelial cell cytokine responses The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 Investegate |Covis Pharma Group Announcements | Covis Pharma Group: COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide) Dexamethasone nanomedicines for COVID-19 Pulmonary surfactant and nanocarriers: Toxicity versus combined nanomedical applications Therapeutic effects of inhaling aerosolized surfactant alone or with dexamethasone generated by a novel noninvasive apparatus on acute lung injury in rats Efficient Interfacially Driven Vehiculization of Corticosteroids by Pulmonary Surfactant Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae Pre-proof Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia Antioxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits Exogenous Surfactant Enhances the Delivery of Recombinant Adenoviral Vectors to the Lung Ambroxol for the treatment of children with acute and chronic respiratory diseases: an overview of efficacy and safety Ambroxol in the 21st century: Pharmacological and clinical update Ambroxol: A multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood Co-aerosolized Pulmonary Surfactant and Ambroxol for COVID-19 ARDS J o u r n a l P r e -p r o o f Journal Pre-proof Intervention: What Are We Waiting for? Therapeutic nucleic acids: current clinical status Molecular mechanisms of RNA interference Maintaining the silence: reflections on long-term RNAi siRNAs: Applications in functional genomics and potential as therapeutics RNAi mechanisms and applications RNAi Therapeutics: Principles, Prospects and Challenges, n.d Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases COVID-19: consider cytokine storm syndromes and immunosuppression Pharmacologic Treatments for COVID-19): A Review On the Alert for Cytokine Storm: Immunopathology in COVID-19 Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome Clinical features of patients infected with 2019 novel coronavirus in Sirna could be a potential therapy for covid-19 Prospects for RNAi Therapy of COVID-19 Molecular targeting of vulnerable RNA sequences in SARS CoV-2: identifying clinical feasibility Alarming COVID variants show vital role of genomic surveillance Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s) ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and Nontargeted Mediators after siRNA Treatment Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells Pulmonary gene delivery using polymeric nonviral vectors T, siRNA delivery to the lung: what's new? Physicochemical properties of nanoparticles regulate translocation across pulmonary surfactant monolayer and formation of lipoprotein corona Effect of pulmonary surfactant on the dissolution, stability and uptake of zinc oxide nanowires by human respiratory epithelial cells Update on Macrophage Clearance of Inhaled Micro-and Nanoparticles Adverse Biophysical Effects of Hydroxyapatite Nanoparticles on Natural Pulmonary Surfactant Investigating the Effect of Particle Size on Pulmonary Surfactant Phase Behavior Metal Nanoparticle Pollutants Interfere with Pulmonary Surfactant Function In Vitro Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A Role of Surfactant Proteins in the interaction of nanoparticles with the air-bloodbarrier Influence of agglomeration and specific lung lining lipid/protein interaction on short-term inhalation toxicity Adsorption of proteins from solution at the solid-liquid interface Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles Endosome maturation, transport and functions Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy Biodegradable dextran nanogels for RNA interference: Focusing on endosomal escape and intracellular siRNA delivery Comparison of J o u r n a l P r e -p r o o f Journal Pre-proof polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: Gene silencing, toxicity and off-target gene expression Functional and Structural Characterization of a Lyophilized Pulmonary Surfactant Directly Applied onto the Air-Liquid Interface Deposition of Aerosolized Lucinactant in Nonhuman Primates Blood, Comparison of poractant alfa and lyophilized lucinactant in a preterm lamb model of acute respiratory distress A model for the structure and mechanism of action of pulmonary surfactant protein B The Late Endosome and Its Lipid BMP Act as Gateways for Efficient Cytosolic Access of the Delivery Agent dfTAT and Its Macromolecular Cargos From Pulmonary There are no conflicts of interest to disclose.